Nuwellis (NUWE) closed at $5.91 on November 3, 2026, up 14.1% from the previous close, on volume of 246,540 shares (30-day average 1,559,497).
Data as of November 3, 2026.
Nuwellis to Report Third Quarter 2026 Financial Results on November 12
Globe Newswire (Wed, 4-Nov 8:30 AM ET)
Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology
Globe Newswire (Tue, 27-Oct 8:00 AM ET)
Globe Newswire (Thu, 8-Oct 8:30 AM ET)
Globe Newswire (Thu, 1-Oct 8:30 AM ET)
Nuwellis taps a 13-year medtech quality veteran as Director of Quality and Regulatory Affairs
Market Chameleon (Thu, 17-Sep 6:58 AM ET)
Globe Newswire (Thu, 17-Sep 8:30 AM ET)
Globe Newswire (Wed, 16-Sep 8:30 AM ET)
Nuwellis Advances Financial Efficiency Strategy with Improved Gross Margins
Globe Newswire (Wed, 9-Sep 8:30 AM ET)
Market Chameleon (Wed, 26-Aug 7:43 AM ET)
Globe Newswire (Tue, 25-Aug 8:30 AM ET)
Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
Nuwellis trades on the NASDAQ stock market under the symbol NUWE.
As of November 4, 2026, NUWE stock price declined to $5.31 with 55,511 million shares trading.
NUWE has a beta of 5.59, meaning it tends to be more sensitive to market movements. NUWE has a correlation of 0.11 to the broad based SPY ETF.
NUWE has a market cap of $2.15 million. This is considered a Sub-Micro Cap stock.
Last quarter Nuwellis reported $2 million in Revenue and -$26.64 earnings per share. This fell short of revenue expectation by $-446,000 and missed earnings estimates by -$25.96.
In the last 3 years, NUWE traded as high as $412,120.70 and as low as $2.52.
NUWE has underperformed the market in the last year with a return of -99.4%, while the SPY ETF gained +13.5%. In the last 3 month period, NUWE fell short of the market, returning -63.4%, while SPY returned +1.6%. However, in the most recent 2 weeks NUWE has outperformed the stock market by returning +7.4%, while SPY returned -0.1%.
NUWE support price is $5.03 and resistance is $6.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NUWE shares will trade within this expected range on the day.